OSM Enhances Angiogenesis and Improves Cardiac Function after Myocardial Infarction

Abstract EN

Oncostatin M (OSM) has been reported to stimulate angiogenesis by upregulating VEGF and bFGF, implying that it could be a therapeutic strategy in treating ischemic diseases.

The present study was aimed at investigating whether OSM could improve cardiac function via prompting angiogenesis following myocardial infarction (MI).

Wild type (WT) and Oβ knock-out (Oβ −/−) mice were, respectively, randomized into sham group, MI + vehicle group, and MI + OSM group.

WT mice displayed significantly impaired cardiac function after MI.

OSM treatment attenuated cardiac dysfunction in WT MI mice, while Oβ deletion abrogated the protective effects.

Besides, OSM attenuated heart hypertrophy and pulmonary congestion evidenced by decreased heart weight/body weight and lung weight/body weight ratio.

Further, reduction of apoptosis and fibrosis in infarct border zone was observed in OSM treated WT MI mice compared with vehicle.

Moreover, in WT mice subjected to MI, OSM treatment significantly increased capillary density along with upregulation of p-Akt and angiogenic factors VEGF and bFGF in comparison with vehicle, and this phenomenon was not found in Oβ −/− mice.

In conclusion, OSM treatment preserved cardiac function, inhibited apoptosis and fibrosis, and stimulated angiogenesis via upregulating VEGF and bFGF in infarct border zone of ischemic myocardium, indicating that OSM could be a novel therapeutic target for MI.